BIOHIT Healthcare Ltd products
Therapeutic Drug Monitoring
Model K9662 - Certolizumab Drug Level ELISA (IDKmonitor)
Certolizumab is the Fab’ fragment of a recombinant humanised antibody conjugated to polyethylene glycol (PEG) and is therefore also known as “certolizumab pegol”. Certolizumab pegol (Cimzia®) is a TNF-alpha inhibitor used for the treatment of chronic inflammatory diseases, such as Crohn’s disease and rheumatoid arthritis. The IDKmonitor Certolizumab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free certolizumab therapeutic drug in serum and EDTA plasma samples allowing clinicians to evaluate the drug efficacy and investigate primary non-response, loss of response and non-remission.
Model K9666 - Ustekinumab Free Anti-drug Antibody ELISA (IDKmonitor)
Ustekinumab is a fully humanised IgG1 therapeutic monoclonal antibody used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. It targets cytokines IL-12 and IL-23 which are involved in immune-mediated inflammatory disorders. The IDKmonitor Ustekinumab Free Anti-drug Antibody ELISA measures free antibodies against ustekinumab (e.g. STELARA®). This assay enables the reliable determination of free, unbound anti-drug antibodies; therefore it is ideal for therapy monitoring when a measurable ustekinumab concentration is not expected, or the unbound fraction of anti-drug antibodies is required, for example shortly before the next infusion. In combination with the drug level determination, the IDKmonitor® Ustekinumab Free Anti-drug Antibody ELISA supports the monitoring and optimisation of therapy.